Source 1primary paper2025MED
Toolkit/Hypoxia-inducible CARs
Hypoxia-inducible CARs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
hypoxia-inducible and SynNotch CARs restrict activity to tumor sites
Usefulness & Problems
Why this is useful
Hypoxia-inducible CARs are described as restricting CAR-T activity to tumor sites. The review presents them as a control strategy for solid-tumor settings.; restricting CAR-T activity to tumor sites
Source:
Hypoxia-inducible CARs are described as restricting CAR-T activity to tumor sites. The review presents them as a control strategy for solid-tumor settings.
Source:
restricting CAR-T activity to tumor sites
Problem solved
The approach is presented as solving the need for more tumor-restricted activity in solid tumors, which is relevant to safety and specificity.; lack of tumor-site-restricted activity; therapy-associated toxicities
Source:
The approach is presented as solving the need for more tumor-restricted activity in solid tumors, which is relevant to safety and specificity.
Source:
lack of tumor-site-restricted activity
Source:
therapy-associated toxicities
Problem links
lack of tumor-site-restricted activity
LiteratureThe approach is presented as solving the need for more tumor-restricted activity in solid tumors, which is relevant to safety and specificity.
Source:
The approach is presented as solving the need for more tumor-restricted activity in solid tumors, which is relevant to safety and specificity.
therapy-associated toxicities
LiteratureThe approach is presented as solving the need for more tumor-restricted activity in solid tumors, which is relevant to safety and specificity.
Source:
The approach is presented as solving the need for more tumor-restricted activity in solid tumors, which is relevant to safety and specificity.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Techniques
No technique tags yet.
Target processes
No target processes tagged yet.
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: actuatorswitch architecture: single chain
Implementation requires a CAR design responsive to hypoxic conditions in the tumor microenvironment. The abstract does not provide the specific sensing mechanism.; requires hypoxia-responsive CAR regulation
Manufacturing complexity and off-target effects remain challenges for engineered CAR-T approaches in solid tumors.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Hypoxia-inducible CARs restrict CAR-T activity to tumor sites.
SynNotch CARs restrict CAR-T activity to tumor sites.
Clinical trials of bispecific CAR-Ts show promise.
Nanobody-based CAR-T cells offer improved stability, tumor penetration, and reduced immunogenicity compared with single-chain variable fragment constructs.
Manufacturing complexity and off-target effects remain challenges for engineered CAR-T approaches in solid tumors.
Armored CARs secreting IL-12 or checkpoint inhibitors remodel the tumor microenvironment.
Cytokine-armed TRUCKs enhance CAR-T persistence and function.
Dual-targeting CARs counter antigen heterogeneity in solid tumors.
Chemokine receptor engineering enhances CAR-T infiltration.
Approval Evidence
1 source1 linked approval claimfirst-pass slug hypoxia-inducible-cars
hypoxia-inducible and SynNotch CARs restrict activity to tumor sites
Source:
activity restrictionsupports
Hypoxia-inducible CARs restrict CAR-T activity to tumor sites.
Source:
Comparisons
Source-stated alternatives
The abstract mentions SynNotch CARs as another tumor-restricted control strategy, along with iCasp9, dasatinib-controlled activation, and cytokine blockade for safety.
Source:
The abstract mentions SynNotch CARs as another tumor-restricted control strategy, along with iCasp9, dasatinib-controlled activation, and cytokine blockade for safety.
Source-backed strengths
described as restricting activity to tumor sites
Source:
described as restricting activity to tumor sites
Compared with coherent anti-Stokes Raman scattering
The abstract mentions SynNotch CARs as another tumor-restricted control strategy, along with iCasp9, dasatinib-controlled activation, and cytokine blockade for safety.
Shared frame: source-stated alternative in extracted literature
Strengths here: described as restricting activity to tumor sites.
Source:
The abstract mentions SynNotch CARs as another tumor-restricted control strategy, along with iCasp9, dasatinib-controlled activation, and cytokine blockade for safety.
Ranked Citations
- 1.